---
title: "REGENXBIO Inc. (RGNX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/RGNX.US.md"
symbol: "RGNX.US"
name: "REGENXBIO Inc."
industry: "Biotechnology"
datetime: "2026-05-20T09:09:36.822Z"
locales:
  - [en](https://longbridge.com/en/quote/RGNX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/RGNX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/RGNX.US.md)
---

# REGENXBIO Inc. (RGNX.US)

## Company Overview

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.regenxbio.com](https://www.regenxbio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: E
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:15.000Z

**Overall: E (0.86)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 361 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: E

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -43.96% |  |
| Net Profit YoY | -83.91% |  |
| P/B Ratio | 13.88 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 292608534.86 |  |
| Revenue | 87822000.00 |  |

#### Multi Score Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -196.43% | E |
| Profit Margin | -330.23% | E |
| Gross Margin | -970.12% | E |
| Revenue YoY | -43.96% | E |
| Net Profit YoY | -83.91% | E |
| Total Assets YoY | -30.36% | E |
| Net Assets YoY | -92.31% | E |
| Cash Flow Margin | 80.61% | C |
| OCF YoY | -43.96% | E |
| Turnover | 0.21 | D |
| Gearing Ratio | 93.83% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - REGENXBIO Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-43.96%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-83.91%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "13.88",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "292608534.86",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "87822000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-196.43%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-330.23%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-970.12%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-43.96%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-83.91%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-30.36%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-92.31%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "80.61%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-43.96%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.21",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "93.83%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.01 | 182/386 | - | - | - |
| PB | 13.88 | 404/386 | 4.42 | 2.97 | 1.83 |
| PS (TTM) | 3.33 | 76/386 | 4.00 | 3.04 | 2.68 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-14T04:00:00.000Z

Total Analysts: **11**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 6 | 55% |
| Overweight | 4 | 36% |
| Hold | 1 | 9% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 5.66 |
| Highest Target | 50.00 |
| Lowest Target | 12.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/RGNX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/RGNX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/RGNX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/RGNX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**